International cost-effectiveness analysis in osimertinib after chemoradiotherapy in stage III EGFR-mutated non-small cell lung cancer
In China, treatment with osimertinib rather than placebo appears to be an effective and economically accessible option for patients with stage III EGFR-mutated NSCLC with no disease progression after chemoradiotherapy. This applied especially to the eastern and central economic regions of China but not the USA currently.
Authors
- Chaochao Wei
- Xi Zou (ORCID: https://orcid.org/0000-0003-2893-3526)
- Xiaoyu Zhang (ORCID: https://orcid.org/0000-0002-2041-9955)
- Diya Tang
Institutions
- Central South University (CN)
- Xiangya Hospital Central South University (CN)
- Hainan Medical University (CN)
- University of South China (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3389/fpubh.2025.1698562
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Hainan Medical University